Marinomed OverviewNovember 2019

2

Disclaimer

This presentation (the “Presentation”) was prepared by Marinomed Biotech AG.

The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.

Certain statements contained in this document may be statements of future expectations and other forward looking statements that are based on management‘s current view and assumptions and involve known and unknown risks and uncertainties that could cause actualresults, performance or events to differ materially from those expressed or implied in such statements.

Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.

This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.

By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.

Marinomed at a Glance

3

4

In-house

▪ Innovation

▪ Product development

▪ Marketed products and clinical pipeline

▪ Patents and IP generation

Marinomed snapshot

Founded in 2006… …Marinomed established two platforms…

…with a lean set-up… …and a strong management team

2006 2008 2010 2012 2016 20182014

platform established

Founded and first financing

in 2006

platform established

clinically validated

IPO and EIB financing

clinically validated

Proven ability to develop revenue

generating products

Proven ability of continued innovation

and IP generation

▪ First causal therapy for colds and flu infections

▪ Six products generating retail sales with 14 partners in more than 40 countries

▪ Successful Phase III for Budesolv (allergic rhinitis) validates platform

▪ Targeting multi-billion Dollar markets (allergic rhinitis, dry eye)

Out-sourced

▪ Production

▪ Marketing

▪ Distribution

▪ Out-licensing of technology

Asset light business model

Helmut Baranyovszki

Operations

Renate Moser

BD & L

Andreas Grassauer

CEO

Eva Prieschl-Grassauer

CSO

Pascal Schmidt

CFO

A lean biopharmaceutical expert in OTC and Rx therapies

Strong half-year allows for accelerated development going forward

Highlights 2019

5Sources: 1. Visiongain 2018

Top-line results for Budesolv

Phase III

Financing raised in Feb 1, 2019 IPO

€22.4m

H1/19 vs. H1/18; +20.7% Q2 vs. Q1

+9.4%

countries launched

>40

6 products on the market, 3 in

advanced pipeline

6 + 3

Venture Debt committed by EIB

€15.0m

market for first product Budesolv

> USD 12 bn1

6Notes: 1. Carregelose Xylometazoline combination, 2. Dissolved Budesonide, 3. Dissolved Tacrolimus

Marinomed delivers new patent protected technologies enabling innovative therapies and unique solutions

Cough,

Cold

, In

fluenza

Allerg

y,

Ophth

alm

ic

PHASE I/II PHASE III LAUNCHED

3 Virus-blocking nasal sprays (two adult and one children formulations)

Virus-blocking decongestant nasal spray (combination with Sorbitol)

Virus-blocking lozenges

Virus-blocking throat spray

Virus-blocking decongestant nasal spray1

Budesolv2

Tacrosolv3

Primary and secondary

endpoints met

PIPELINE

Marinosolv® allows to provide Budesonide in solution offering a competitive edge

7

Marinosolv® explained based on Budesolv

SuspensionRhinocort Aqua Budesonide nasal spray64µg per dose/spray

SolutionMarinosolv® enabled

Budesonide nasal spray10µg per dose/spray

Marinosolv® – a technology platform with the potential to facilitate delivery of any compound with solubility issues

USPs

Increased bioavailability

Dose reduction

Aseptic filtering

Faster onset of actionHigher local, lower systemic availability

Lower possible side effectsLower production costs

Preservative free formulationLower production costs

Properties

Proven solubility

Increasing market

Patent protected

Solubility increase versus water shown for variety of compounds

Higher specificity of compounds leads to lower solubility → increasing number of APIs that could benefit from Marinosolv

Patent in nationalisation phase

38%

43%

12%

7%

corticosteroids antihistamines immunotherapy other

47%

35%

15%3%

▪ Budesolv showed a pronounced reduction of allergic nasal symptoms in less than 3 hours

▪ Budesolv achieved non-inferiority, i.e. at least the same effect as marketed product (Rhinocort Aqua) on D8

▪ Budesolv has ~ 85% less of the dose of the marketed product and is preservative free

▪ Prominent reduction of respiratory symptoms

Positive Top-line results

Addressable market with 5% growth1

8

▪ Approval process can be continued as planned

▪ H2/2019 – generation of stability data

▪ H1/2020 – application for market approval

▪ 280 days later (plus clock stops) – expectedapproval

▪ 2021 - launch

Market approval process on track

▪ Platform validation: Marinosolv enables novel stable aqueous formulations of hardly soluble compounds

▪ Next compound is Tacrosolv, a phase II asset in preparation for clinical development

▪ Additional compounds in review

Additional potential

Source: 1. Visiongain Allergic Rhinitis 2018

Marinosolv® with significant milestones

Progress as promised with future untapped potential

2019USD

13.0bn

2028USD

17.4bn

Budesolv has the potential to become a blockbuster product

9Sources: GlobalData, Visiongain 2018, OTC yearbook 2018 by N. Hall,

Budesolv – redefining the market for allergic rhinitis

▪ Target market Allergic Rhinitis $12.2bn

▪ Steroids in Allergic Rhinitis growing 5.4%annually from $5.0bn to $8.3bn in 2028

Rhinocort Flixonase Budesolv

Owner

Revenue 2017 ($m)

250 1,570Phase III completed

Onset of action

1-2 weeks 4-5 days <3 hours

Potency of API

Budesolv is expected to outcompete the originator drug and to grab market share from the leaders

New Class

▪ First aqueous solution▪ First compound active after minutes▪ ~85% less dose compared to originator

Clinically Proven

▪ Successful clinical phase III▪ Equivalent effect compared to originator▪ Fast onset of action

Huge Market Opportunity

▪ Clinically relevant differentiation compared to marketed products

▪ Unsatisfied need for fast relief

Attractive Go-to-Market

▪ De-risked compound based on approved substances

▪ On track for market approval in 2021▪ Patent protected until 2036

Very promising preclinical data1 Risk reduced clinical strategy

Tacrosolv – a powerful immunmodulator

10Sources: 1. Siegl et al., Eur J Pharm Biopharm, Jan 2019; 2 GlobalData, Visiongain 2017

Highly potent API with Marinosolv and smart clinical approach for new eye indications

Unmet medical need reflected in market figures2

1,7

4,00,1

1,1

0,3

0,3

0,1

0,3

0,0

2,0

4,0

6,0

2016 2026

Market for Dry Eye

US EU5 Japan China

Novartis acquires Xiidra (in dry eye) from Takeda in a deal worth $3.4bn cash plus $1.9bn milestones

Corn

ea

Dispersion

Retina

Allergic Conjunctivitis

Phase II

Dry Eye

Phase III

With successful Phase II in allergic conjunctivitis, likely, Phase II for Dry

Eye can be skipped

Dispersion

1,0

1,1

1,2

1,3

1,4

1,5

2013 2014 2015 2016 2017 2018

Revenues in $bn (US+EU5)

Challenge study for dose finding

Market for Allergic Conjunctivitis

Indication for market potential

▪ Colds are caused by more than 200 different respiratory viruses

▪ Carragelose® creates a protective layer that reduces the spreading and proliferation of the common cold virus

▪ Trapped viruses leave the body via the natural route → The cold is either prevented or is significantly shorter in duration

Mode of action

▪ 3 Double-blind, placebo-controlled clinical trials with a total of 450 patients

▪ Reduction in duration of disease as well as fewer relapses during 21 days of observation period

Days1

▪ Significant reduction of common cold symptoms in the 2nd phase of the disease (p=0,048)1.

Shortening of symptoms clinically proven

Carragelose® with innovative mode of action

11Source: 1. Ludwig et al. Respiratory Research; 2013 Note: TSS = Total Symptom Score,

Carragelose® blocks viral attachment to cells via an unspecific physical mechanism

Cum

ula

tive p

atients

without

sym

pto

ms (

%)

Daily r

eduction o

fsym

pto

ms (

TSS)

▪ Canada1

▪ Denmark2

▪ Finland

▪ Norway

New product and country launches in 2019

12

Carragelose® products continue expansion

Multiple additional launches and line extensions planned in the coming years

(HU)

(DE)

(CH)

(Baltics) (Nordics)(Canada)

(Multiple)(Multiple) (Multiple)

Current commercial reach

(AT)

(GR)

▪ Slovakia

▪ Thailand

▪ Vietnam

(Multiple)

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Anti-viral decongestant nasal spray

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Anti-viral cold/flu nasal spray (higher dose)

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Anti-viral cold/flu nasal spray

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Anti-viral throat spray

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Anti-viral kids nasal spray

Anti-viral lozenges

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Global distribution partners

Currently marketed in over 40 countries

Legend

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris pro Coldamaris pro junior Coldamaris plus

Regulatory status

Active ingredients

0.4 mg/ml Kappa-

Carrageenan

Patient population For adults and children 1y+ Children 1y+ For adults and children 1y+

Spray volume 140µl/puff 50µl/puff 140µl/puff

Alleviate the severity of

cold symptoms, can

reduce new infections

Can shorten the duration

of flu-like illnesses and

alleviate the severity of

cold symptoms, can

reduce new infections

Austrian product version

Medical device IIa

1.2 mg/ml Carragelose®

Claims

Is indicated for the prophylactic and supportive treatment of viral infections of the

respiratory tract

Can shorten the duration of common cold and resurgence of virus-related cold

symptoms

Can be used additionally for the preventive and sustainable moistening of the

nasal mucosa and thus for the prophylactic and supportive treatment of all

complaints resulting from dry and irritated nasal mucosa

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

Coldamaris lozenges Coldamaris throatspray Coldamaris akut

Regulatory status Medical device Is

Active ingredients 10 mg Carragelose®

0.4 mg/ml Kappa-

Carrageenan

7% Sorbitol

Patient population For adults and children 6y+

Spray volume n.a.

Clears a blocked nose

particularly during

common colds (flu-like

illnesses) caused by

viruses, allergic or non-

allergic rhinitis as well as

sinusitis

Can shorten the duration

of common colds (flu-like

illnesses), reduce the

severity of cold symptoms

and can reduce new

infections and resurgence

of virus-related cold

symptoms

For moistening the mouth

and throat in case of dry

breathing air, cough or

hoarseness for example

Can be used for the

prevention and supportive

treatment of common cold

and flu-like illnesses and

serve to moisten the lining

of the mouth and throat

For moistening of the oral

and pharyngeal mucosa in

case of e.g. cough,

hoarseness or dry

breathing air

caused by e.g. smoking,

long speaking or singing

Austrian product version

Medical device IIa

Claims

1.2 mg/ml Carragelose®

For adults and children 1y+

140µl/puff

For prevention and supportive treatment of viral

infections of the upper respiratory tract

For the prevention and supportive treatment of all

complaints resulting from dry or irritated oral and

pharyngeal mucosa

1 Additional partner for new product in Canada

2 Former partner for Denmark has been acquired by KARO Pharma; new product launch under new brand

Marinosolv® in the focus

▪ Targeting a 5 billion dollar market with lead product

▪ Regulatory submission of Budesolv set to take place in 2020

▪ Clinical phase II of Tacrosolv in first half 2020

▪ Further developments based on Marinosolv® technology for strong growth perspective

Carragelose® is back on growth trajectory

▪ Entry into new markets and additional product launches in existing markets

▪ Investments in clinical studies and the optimisation of production

▪ Long-term rise in revenues expected

We remain optimistic for 2019 and beyond

▪ Increasing order and sales performance expected

▪ Ramp up of R&D investments

▪ Funding provided by IPO proceeds, EIB loan commitment, subsidies and recurring revenues

Positive outlook for 2019 and beyond

13

Exploiting the potential of our platforms Marinosolv® and Carragelose®

www.marinomed.com